BOEHRINGER INGELHEIM VIRAMUNE INDICATION SHOULD NOT BE LIMITED TO ADVANCED HIV; DRUG INTERACTION STUDIES NEEDED: FDA CMTE. RECOMMENDS APPROVAL
Executive Summary
Boehringer Ingelheim's Viramune (nevirapine) indication should not be limited to HIV patients who have experienced disease progression while receiving approved therapies, FDA's Antiviral Drugs Advisory Committee concluded at the review of Viramune June 7.